CTAG1B and melanoma: For example, a recent vaccine trial using recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 showed that 72% of patients with unresectable melanoma whose tumors expressed NY-ESO-1 had clinical benefit from this therapy (defined as complete, partial, mixed response or disease stabilization) [21].